Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200-Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $47.38 and traded as high as $59.26. Global X Genomics & Biotechnology ETF shares last traded at $58.45, with a volume of 22,895 shares trading hands.

Global X Genomics & Biotechnology ETF Stock Up 2.3%

The firm has a market capitalization of $88.55 million, a PE ratio of -25.06 and a beta of 1.16. The business’s fifty day moving average price is $49.83 and its 200 day moving average price is $47.46.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently disclosed a dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were paid a dividend of $0.0579 per share. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is currently -27.35%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GNOM. IFP Advisors Inc increased its holdings in shares of Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after purchasing an additional 489 shares during the period. Wealth Management Partners LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 1st quarter worth $244,000. Creative Financial Designs Inc. ADV boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at about $575,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.